Immunology company Nucleome Therapeutics announced on Monday the appointment of Dr Michelle Morrow as its chief scientific officer (CSO), effective 23 February 2026.
Dr Morrow has two decades of experience in drug discovery and development and executing R&D strategy across biotech and large pharma.
Most recently Dr Morrow was CSO at Avacta Therapeutics, providing strategic leadership of discovery and preclinical research and leading its oncology programme through candidate selection to IND approval. Earlier, she was SVP, head of invoX Therapeutics Innovation, following its acquisition of F-star Therapeutics.
Newbury Pharmaceuticals secures first Scandinavian approval for palbociclib generic
Philips secures FDA clearance for Spectral CT Verida system
Circio partners with Acuitas to evaluate in vivo CAR-T cell therapy technology
Asgard Therapeutics appoints chief medical officer
Mestag Therapeutics to present targeted LTBR agonist MST-0312 at AACR Annual Meeting
Senhwa Biosciences secures up to TWD500m funding for AI-driven drug development
Kazia Therapeutics in-licenses SETDB1 inhibitor drug development platform
Kelun-Biotech reports Phase II study results for sac-TMT at 2026 SGO
Genmab reports positive safety data for Rina-S combination in ovarian cancer
GSK reports strong early-stage data for B7-H4 ADC in gynaecological cancers
FDA grants priority review to ifinatamab deruxtecan in small cell lung cancer